Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI)
Evaluates bone marrow response to anemia, often in sickle cell patients.
This tool provides multiple calculations:
- Absolute reticulocyte count:
- The number of reticulocytes in a volume of blood.
- Use when a direct measure of red blood cell production is needed, such as in early treatment response or non-anemic conditions with altered RBC turnover.
- Corrected reticulocyte percentage/reticulocyte index (RI):
- Adjusts the reticulocyte percentage to account for the degree of anemia.
- Can be appropriate as a quick assessment of marrow response in mild to moderate anemia, where adjusting for maturation time may not be necessary.
- Reticulocyte production index (RPI):
- Adjusts the reticulocyte index to account for the longer maturation time of reticulocytes released prematurely from the bone marrow.
- Useful in moderate to severe anemia, where reticulocytes are often released early.
An elevated RI or RPI suggests a responsive bone marrow, which may be seen in:
-
Recent bleeding.
-
Hemolysis.
-
Response to anemia treatments (e.g., iron or vitamin supplementation).
-
Bone marrow recovery (e.g., after chemotherapy or transplantation).
A low RI or RPI suggests marrow suppression or ineffective erythropoiesis, which may be seen in:
-
Nutritional deficiencies (e.g., vitamin B12, iron, folate).
-
Reduced erythropoietin production (e.g., chronic renal failure).
-
Bone marrow failure syndromes (e.g., aplastic anemia).
-
Bone marrow replacement (e.g., metabolic storage disease, sarcoidosis).
-
Malignant conditions (e.g., lymphoma, leukemia).
An evaluation for inadequate marrow response may include:
-
Iron, ferritin, total iron-binding capacity (TIBC), vitamin B12, and folate levels to assess for iron deficiency anemia or other nutrient deficiencies.
-
A review of the patient’s history for chronic inflammatory, renal, or endocrine diseases that could cause anemia of chronic disease.
-
If no clear cause is identified through initial testing, consider a bone marrow biopsy to assess for primary bone marrow disorders, such as aplastic anemia, myelodysplastic syndrome, or other marrow infiltrative processes.
-
For cases where anemia etiology remains unclear or if a bone marrow disorder is suspected, a referral to hematology is warranted for further evaluation and management.